FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

• Published in: Clinical cancer research 2015-08, Vol.21 (16), p.3586-3590
• Main Authors: de Claro, R Angelo, McGinn, Karen M, Verdun, Nicole, Lee, Shwu-Luan, Chiu, Haw-Jyh, Saber, Haleh, Brower, Margaret E, Chang, C J George, Pfuma, Elimika, Habtemariam, Bahru, Bullock, Julie, Wang, Yun, Nie, Lei, Chen, Xiao-Hong, Lu, Donghao Robert, Al-Hakim, Ali, Kane, Robert C, Kaminskas, Edvardas, Justice, Robert, Farrell, Ann T, Pazdur, Richard
• Format: Article
• Language: English
• Subjects: Aged; Clinical Trials as Topic; Drug Approval - legislation & jurisprudence; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Lymphoma, Mantle-Cell - drug therapy; Lymphoma, Mantle-Cell - pathology; Male; Middle Aged; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - adverse effects; Pyrazoles - pharmacokinetics; Pyrazoles - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Pyrimidines - therapeutic use; United States
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-14-2225

On November 13, 2013, the FDA granted accelerated approval to ibrutinib (IMBRUVICA capsules; Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. On February 12, 2014, the FDA granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that received all four expedited programs of the FDA: Fast-Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval. Both approvals were based on overall response rate (ORR) and duration of response (DOR) in single-arm clinical trials in patients with prior treatment. In MCL (N = 111), the complete and partial response rates were 17.1% and 48.6%, respectively, for an ORR of 65.8% [95% confidence interval (CI), 56.2%-74.5%]. The median DOR was 17.5 months (95% CI, 15.8-not reached). In CLL (N = 48), the ORR was 58.3% (95% CI, 43.2%-72.4%), and the DOR ranged from 5.6 to 24.2 months. The most common adverse reactions (≥ 30% in either trial) were thrombocytopenia, diarrhea, neutropenia, bruising, upper respiratory tract infection, anemia, fatigue, musculoskeletal pain, peripheral edema, and nausea.